




Contents lists available at ScienceDirect

Asian Pacific Journal of Tropical Biomedicine

journal homepage: www.elsevier.com/locate/apjtb



Document heading doi:10.1016/S2221-1691(11)60083-X © 2011 by the Asian Pacific Journal of Tropical Biomedicine. All rights reserved.

Analytical characterization and structure elucidation of metabolites from *Aspergillus ochraceus* MP2 fungi

Meenupriya J¹, Thangaraj M²¹Department of Biotechnology, Sathyabama University, Chennai-119, India²CAS in Marine biology, Annamalai university, Parangipettai- 608 502, India

ARTICLE INFO

Article history:

Received 5 March 2011

Received in revised form 4 April 2011

Accepted 20 April 2011

Available online 10 May 2011

Keywords:

Marine sponge derived fungi

Aspergillus ochraceus

Bioactive metabolites

Antibacterial activity

Analytical characterization

Fungi

Aspergillus

Bioactive secondary metabolite

Antagonistic human pathogen

Antimicrobial activity

Bioactive compounds

ABSTRACT

Objective: To isolate and characterize the bioactive secondary metabolites from *Aspergillus ochraceus* (*A. ochraceus*) MP2 fungi. **Methods:** The anti bacterial activity of marine sponge derived fungi *A. ochraceus* MP2 was thoroughly investigated against antagonistic human pathogens. The optimum inhibitory concentration of the fungi in the elite solvent was also determined. The promising extracts that showed good antimicrobial activity were subjected to further analytical separation to get individual distinct metabolites and the eluants were further identified by GC MS instrumental analysis. The molecular characterization of the elite fungal strains were done by isolating their genomic DNA and amplify the internal transcribed spacer (ITS) region of 5.8s rRNA using specific ITS primer. The novelty of the strain was proved by homology search tools and elite sequences was submitted to GENBANK. **Results:** Three bioactive compounds were characterized to reveal their identity, chemical formula and structure. The first elutant was identified as α - Campholene aldehyde with chemical formula $C_{10}H_{16}O$ and molecular weight 152 Da. The second elutant was identified as Lucenin-2 and chemical formula $C_{27}H_{30}O_{16}$ and molecular weight 610 Da. The third elutant was identified as 6-Ethyl-3-yl-2-ethylhexyl ester with Chemical formula $C_{26}H_{42}O_4$ with molecular weight 418 Da. **Conclusions:** The isolated compounds showed significant antimicrobial activity against potential human pathogens. Microbial secondary metabolites represent a large source of compounds endowed with ingenious structures and potent biological activities.

1. Introduction

Many marine invertebrates produce natural compounds that affect the growth, metabolism, reproduction, and survival of other types of organisms. Hence, they are considered to be bioactive. Those include potentially effective therapeutic agents with antiviral, antibacterial, and antitumor properties produced by invertebrates from the classes Porifera, Cnidaria, Mollusca, Echinodermata, Bryozoa, and Urochordata. Close relations between marine invertebrate species and microorganisms, including symbiotic associations and interactions during larval settlement, have been characterized and this provides insights to the regulation of host-symbiont-microbial community interactions. Many of the compounds isolated from marine organisms, such as sponges, may be produced

by associated microbes. Marine sponges are benthic animals found in the widerange of marine environments. The diversity of sponges species is superior in the tropical coral reef environments. The sponges are also very important resources for searching the biologically active substances, which are useful to develop pharmaceuticals, agrochemicals and biochemical reagents and their lead compounds[1]. The origins of these biologically active substances are recently thought to be the metabolites produced by the microorganisms associated with the sponges. And studies have also suggested that some bioactive compounds isolated from marine organisms have been shown to exhibit anti-cancer, anti-microbial, anti-fungal or anti-inflammatory and other pharmacological activities[2-9]. These marine invertebrates have evolved chemical defense mechanisms against other invading organisms, which involve the production of secondary metabolites[10]. Sponges are good homes not only for macro organisms, such as worms, brittlestars, shrimp, crabs, etc., but also for a variety of microorganisms such as bacteria, fungi, and microalgae,

*Corresponding author: J Meenupriya, Department of Biotechnology, Sathyabama University, Chennai-119, India.
Tel: +91 44 24501644
E-mail: meenupriya.j@gmail.com

which live in the canals, between cells, and even inside the cell^[11]. A variety of antimicrobial substances have been isolated from various species of marine sponges^[12]. Up to 800 antibiotic compounds have been isolated from marine sponges, a number of which corroborates assumptions that sponges appear to defend themselves against infections by producing and/or accumulating secondary metabolites. *Aspergillus ochraceus* (*A. ochraceus*) can produce other secondary metabolites, whose biological activity has not been characterized until now. These molecules may be beneficial (antibiotics) or harmful (mycotoxins) to human health^[13–15].

Fungi isolated from marine sponge have a high creativity index, *i.e.*, ability to synthesize new and interesting secondary metabolites. Although the natural function is not known, it is assumed that they play an important role in chemical defense and communication of the organism^[16]. Many of them have been suggested to act as pheromones, antifeedants or repellents and regulators in the development of organisms. The secondary metabolite does not occur randomly but is correlated with ecological factors^[17]. Nevertheless, a growing number of metabolites from sponge-derived fungal strains has been reported in the last years^[18]. It provides an overview of sponge species investigated, taxonomy of isolated fungi, and reported metabolites. These structures suggest most of the metabolites to be derived from metabolic pathways is also common to terrestrial fungi. Such a similarity is, for example, obvious for sesquiterpenes of the hirsutane-type^[16]. Studies show that secondary metabolites in sponges play a crucial role in their survival in the marine ecosystem. These natural products have interesting biomedical potential, pharmaceutical relevance and diverse biotechnological applications^[18]. The biomedical and pharmaceutical importances of these compounds are attributed to their antiviral, antitumor, antimicrobial and general cytotoxic properties^[12]. Interestingly, out of the 13 marine natural products that are currently under clinical trials as new drug candidates, 12 are derived from invertebrates. Among them, Porifera remains the most important phylum, as it provides a greater number of natural products, especially novel pharmacologically active compounds^[19]. Biochemical characteristics seem to be useful taxonomic markers and good indicators of sponge phylogeny^[20]. The diversity of biochemical properties of sponges has been demonstrated by the continued discovery of novel compounds that have pharmacological properties^[21].

2. Materials and methods

2.1. Collection of sponge

Specimens were collected by SCUBA diving using hammer and chisel from Gulf of Mannar, located at 215 kms from Kanyakumari District, in the narrow strip of peninsular land along the south east coast of Tamilnadu state.

2.2. Isolation of fungi

The sponge sample was washed with sterile water (distilled water: sea water; 1:1) and ground in a mortar and pestle under aseptic conditions. Serial dilution was performed and from each dilution, plating was done in Sabourauds agar by spread plate technique. The plates were then incubated at 27 °C for 5 days. After 5 days, the plates were examined and the pure culture was isolated on pure agar plate.

2.3. Molecular characterization and identification of elite fungi by ITS sequencing

The fungi were grown in culture in potato dextrose broth at room temperature in the dark for 48 to 72 hours. The genomic DNA was isolated and the internal transcribed spacer (ITS) region of 5.8sRNA was amplified using primer ITS1 TO 5' TCCGTAGGTGAACCTGCCG 3' and primer ITS5 5' TCCTCCGCTTATTGATATGC 3' 7 and sequenced using automated sequencer.

2.4. Mass cultivation of *A. ochraceus*

A. ochraceus Wilhelm NRRL 3174 was grown on synthetic agar medium (SAM) of the following composition: 3 g/L NH₄NO₃, 26 g/L K₂HPO₄, 1 g/L KCl, 1 g/L MgSO₄·7H₂O, 10 mL of mineral solution (containing distilled water per litre, 70 mg Na₂B₄O₇·10H₂O, 50 mg (NH₄)₆·Mo₇O₂₄·4H₂O, 1 000 mg FeSO₄·7H₂O, 30 mg CuSO₄·5H₂O, 11 mg MnSO₄·H₂O, and 1 760 mg ZnSO₄·7H₂O; the pH was adjusted to 2 with 2 mol/L HCl), 15 g agar, and 50 g/L glucose. The pH of the medium was adjusted to 6.5 by 2 mol/L HCl and autoclaved at 120 °C for 20 minutes.

2.5. Extraction process

The fungal mycelia were homogenized using sea water. Then the biomass was subjected to an extraction of biologically active components which were carried out with different solvents in the order of increase polarity: Chloroform, butanol and ethyl acetate by soaking at ambient temperature. The crude extracts obtained were dried under rotary vacuum evaporator and screened for anti-bacterial activity.

2.6. Antimicrobial assay

Agar diffusion assay is used widely to determine the antibacterial activity of crude extract. The technique works well with defined inhibitors. Nutrient agar was prepared and was poured in the petri dish and allowed for solidification, 24 hours growing bacterial culture were swabbed on it. The wells (8 mm diameter) were made by using cork borer. The difference concentration of the crude extract were loaded in the well. The plate was then inoculated at 37 °C for 24 hours.

Dilution assay is a standard method used to compare the inhibition efficiency of the antimicrobial agents. Nutrient broth was inoculated with 24 hours growing bacterial culture and different concentrations of the extract were inoculated.

Bacterial culture inoculated in nutrient broth were used as control. The tubes were incubated at 37°C for 24 hours. The optimal densities were measured spectrometrically at 600 nm. The percentage of viable cell was calculated using the following formula:

$$\% \text{ Viable cells} = \frac{\text{Control OD} - \text{Test OD} \times 100}{\text{Control}}$$

2.7. Thin layer chromatography

TLC is used to separate the compound present in the crude extract. The separation of the compound also depends on the usage of the solvent. The drug with the concentration of 1 mg/mL was plotted on the TLC plate and dried. It was then run with different solvent ratio the spots were identified both in the uv light and in the iodine chamber. The R_f value was calculated using the formula:

$$R_f \text{ value} = \frac{\text{Distance travelled by the solute}}{\text{Distance travelled by the solvent}}$$

2.8. Gas chromatography–mass spectrometry (GCMS) analysis

The crude extract was quantified using gas chromatograph (GCMS–Shimadzu) equipped with a DB–5 ms column (mm inner diameter 0.25 mm, length 30.0 m, film thickness 0.25 μ m) mass spectrometer (ion source 200 °C, RI 70 eV) programmed at (40–650) °C with a rate of 4 °C/min. Injector temperature was 280 °C; carrier gas was He (20 psi), column flow rate was 1.4mL/min, injection mode –split.

3. Results

3.1. Isolation of fungi

In the present study, the 10^{-5} dilution of the sponge sample yielded three different isolates. The characterization and analysis was performed for Isolate 1. Pure culture of Isolate 1 (Figure 1a) was obtained and SEM micrograph (Figure 1b) was taken to visualize the morphological features of the fungi.

3.2. Molecular characterization and identification of elite fungi

Table 1

Zone of inhibition of fungal filtrate in different solvents (mm).

Pathogen	Butanol (μ L)				Chloroform (μ L)				Ethyl acetate (μ L)			
	25	50	75	100	25	50	75	100	25	50	75	100
<i>Pseudomonas</i>	–	–	–	–	12	12.5	14	15	14	16.5	18	19
<i>Klebsiella</i>	–	–	–	–	11	13	15	15	17	19	20	23
<i>S. aureus</i>	–	–	–	–	11	14	18	21	15	17	23	25

Table 2

Well diffusion assay–standardization (ethyl acetate–low concentration and high concentration).

	Concentration (μ L)	<i>Klebsiella</i> (mm)	<i>Pseudomonas</i> (mm)	<i>Staphylococcus</i> (mm)	<i>Micrococcus</i> (mm)
Low concentration	25	–	–	–	–
	50	–	11	11	–
	75	11	12	12	–
	100	12	13	13	11
High concentration	250	12	11	21	17
	500	14	16	23	19
	750	16	18	23	20
	1 000	19	20	24	24

Table 3

Percentage of viable cells of *Staphylococcus* and *Micrococcus* in varying concentrations of ethyl acetate.

Concentration (μ L)	% of viable cells of <i>Staphylococcus</i>	% of viable cells of <i>Micrococcus</i>
100	7.532	7.399
200	12.727	13.452
300	13.766	16.591
400	26.753	18.161
500	27.532	28.475
600	30.389	34.977
700	46.233	40.132
800*	52.207	46.188
900**	71.428	54.484
1000	75.064	83.408

*MIC for *Staphylococcus*; **MIC for *Micrococcus*.

The ITS region is now perhaps the most widely sequenced DNA region in fungi, It is most useful for molecular systematics at the species level, and even within species. In the present study, the DNA was isolated from the Isolate 1 and the ITS region of 5.8s rRNA was amplified using specific primers ITS1 and ITS4 and the sequence was determined using automated sequencers. Blast search sequence similarity was found against the existing non redundant nucleotide sequence database thus, identifying the fungi as *Aspergillus ochraceus*. The percentage of similarity between the fungi and database suggests it as novel strain. Thus, the novel strain was named as *A. ochraceus* strain MP2 and made publically available in GenBank with an assigned accession number .




Figure 1. a: Pure culture of Isolate 1; b: SEM micrograph of Isolate 1.

3.3. Anti-microbial assay

The fungi *A. ochraceus* MP2 was extracted in three solvents of varying polarity (Butanol, chloroform, ethyl acetate). Three human pathogens namely *Klebsiella pneumonia* ATCC 15380, *Staphylococcus aureus* ATCC 25923, *Pseudomonas aeruginosa* ATCC 27853 were used to test the anti-microbial activity. Their zone of inhibition in varying concentrations of the sample is given in Table 1.

Ethyl acetate provided promising results compared to the other solvents. Therefore, the optimum concentration of ethyl acetate producing maximum inhibition of the pathogen was analyzed using the same well diffusion assay for both low concentration [(25-100) μ L] and high concentration [(250-1 000) μ L] of the solvent. Their zone of inhibition is shown in Table 2.

Higher concentration of ethyl acetate provided a better inhibition activity compared to their low concentration counterpart. The minimum inhibition concentration (MIC) of the elite solvent was standardised for two pathogens *Staphylococcus* and *Micrococcus* using broth dilution assay and the result is in Table 3.

The fungal extract subjected to TLC separation revealed the presence of three bioactive metabolites which was visualised in UV short range spectrum of 254 nm (Figure 2a), UV long range of 365nm (Figure 2b) and iodine chamber (Figure 2c).

The TLC band was eluted and the bioactive metabolites in the eluant responsible for the anti bacterial activity were characterized using GC-MS. The chromatogram (Figure 3) revealed the presence of different functional groups in the eluant and the solvent. Three dominant compounds were individually characterized to reveal their identity, chemical

formula and structure. The first elutant was identified as α - Campholene aldehyde with Chemical formula $C_{10} H_{16} O$ and molecular weight 152 Da. The second elutant was identified as Lucenin-2 with Chemical formula $C_{27} H_{30} O_{16}$ and molecular weight 610 Da. The third elutant is identified as 6-Ethyl oct - 3-yl- 2- ethylhexyl ester with Chemical formula $C_{26} H_{42} O_4$ and molecular weight 418 Da.




Figure 2. TLC strip visualised in a. UV short range b. UV long range c. Iodine chamber.

4. Discussion

World's oceans cover more than 70% of the earth's surface and marine biota are an enormous yet underutilized resource for the discovery of neutraceuticals, pharmaceuticals and other high value, low volume bioactives[22]. Marine-derived fungi have been recognized as a potential source of structurally novel and biologically potent metabolites, and a growing number of marine fungi have been reported to produce novel bioactive.

secondary metabolites[23-25] of the 18000 marine natural products described, over 30% are from sponges and of the antitumor natural product patent registrations in recent years over 75% are from sponges[26,27]. Especially, the genus *Aspergillus* has been known to be a major contributor to the secondary metabolites of marine fungal origin, for example, four sesquiterpenoids with a unique nitrobenzyl ester from *Aspergillus versicolor* (*A. versicolor*), two modified cytotoxic tripeptides from *Aspergillus* sp., novel pentacyclic oxindole alkaloid from *Aspergillus tamarii*[28], four prenylated indole alkaloids from *Aspergillus* sp.[29] and two cyclopentapeptides from *A. versicolor*[30]. This paper reports the isolation of three bioactive compounds from *A. ochraceus*. The antimicrobial activities of the isolated pure compounds in ethyl acetate solvent were reported since ethyl acetate extract showed promising results in *Aspergillus flavus*[31]. The isolated compounds showed significant antimicrobial activity against potential human pathogens. Microbial secondary metabolites has a large source of compounds endowed with ingenious structures and potent biological activities. Many of the products currently used for human or animal therapy, in animal husbandry and in agriculture are produced by microbial fermentation, or derived from chemical modification of a microbial product[32]. The present study of screening bioactive secondary metabolites revealed *A. ochraceus* as a source for the production of three effective metabolites. These metabolites can be further exploited

for the biotechnological applications in medicine and agriculture.

Conflict of interest statement

We declare that we have no conflict of interest.

References

- [1] Pietra. Secondary metabolites from marine microorganisms: bacteria, protozoa, algae and fungi. Achievements and prospects. *Nat Prod Rep* 1997; **14**: 453–464.
- [2] Donia M, Hamann MT. Marine natural products and their potential applications as anti-infective agents. *Lancet* 2003; **3**: 338–348.
- [3] Gul W, Hamann MT. Indole alkaloid marine natural products: an established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. *Life Sci* 2005; **78**: 442–453.
- [4] Haefner B. Drugs from the deep: marine natural products as drug candidates. *Drug Discov Today* 2003; **8**: 536–544.
- [5] Jha RK, Xu Z. Biomedical compounds from marine organisms. *Mar Drugs* 2004; **2**: 123–146.
- [6] Proksch P, Edrada RA, Ebel R. Drugs from the seas—current status and microbiological implications. *Appl Microbiol Biotechnol* 2002; **59**: 125–134.
- [7] Mayer AM, Hamann MT. Marine compounds with anthelmintic, antibacterial, anticoagulant, antidiabetic, antifungal, anti-inflammatory, antimalarial, antiplatelet, antiprotozoal, antituberculosis, and antiviral activities; affecting the cardiovascular, immune and nervous systems and other miscellaneous mechanisms of action. *Comp Biochem Physiol* 2005; **140**: 265–286.
- [8] Venkateswara Rao J, Desai D, Vig PJS, Venkateswarlu. Marine biomolecules inhibit rat brain nitric oxide synthase. *Toxicol* 1998; **129**: 103–110.
- [9] Venkateswarlu Y, Srinivasa Reddy N, Venkatesham U. Novel bioactive compounds from the soft corals: chemistry and biomedical applications. Bio-organic compounds: *Chem Biomed Appl* 2001; **6**: 101–128.
- [10] Li Kam Wah H, Jhaumeer-Laulloo S, Choong Kwet Yive R, Bonnard I, Banaigs B. Biological and chemical study of some soft corals and sponges collected in Mauritian waters, Western Indian Ocean. *J Mar Sci* 2006; **5**: 115–121.
- [11] Kobayashi M, Higuchi K, Murakami N, Tajima H, Aoki S. Callystatin A, a potent cytotoxic polyketide from the marine sponge, *Callyspongia truncata*. *Tetrahedron Lett* 1999; **38**: 2859–2862.
- [12] Wang G. Diversity and biotechnological potential of the sponge-associated microbial consortia. *J Ind Microbiol Biotechnol* 2006; **33**: 545–551.
- [13] Jayant N, Suresh R. Moderate protective effect of 6-MFA, a microbial metabolite obtained from *Aspergillus ochraceus* on immunological liver injury in mice. *Comp Immunol Microbiol Infect Dis* 1999; **22**: 15–25.
- [14] Marquardt RR, Frohlich AA. A review of recent advances in understanding ochratoxinosis. *J Anim Sci* 1992; **70**: 3968–3988.
- [15] Schwartz R, Liesch J, Hensens O, Zitano L, Honeycutt S, Garrity G, et al. A novel antifungal agent: fermentation, isolation, structural elucidation and biological properties. *J Antibiot* 1988; **41**: 1774–1779.
- [16] Fiedler HP, Bruntner C, Riedlinger J, Bull AT, Knutsen G, Goodfellow M, et al. Proximicin A, B and C, novel aminofuran antibiotic and anticancer compounds isolated from marine strains of the actinomycete *Verrucosipora*. *J Antibiot* 2008; **61**: 158–163.
- [17] Wagner Dobler I, Beil W, Lang S, Meiners M, Laatsch H. Integrated approach to explore the potential of marine microorganisms for the production of bioactive metabolites. *Adv Biochem Eng Biotechnol* 2002; **74**: 207–238.
- [18] Jensen PR, Fenical W. Strategies for the discovery of secondary metabolites from marine bacteria: ecological perspectives. *Annu Rev Microbiol* 1994; **48**: 559–584.
- [19] Gunasekera AS, Sfanos KS, Harmody DK, Pomponi SA, McCarthy PJ, Lopez JV. An enhanced database of the microorganisms associated with deeper water marine invertebrates. *Appl Microbiol Biotechnol* 2004; **66**: 373–376.
- [20] Kobayashi J, Ishibashi M. Bioactive metabolites of symbiotic marine microorganisms. *Chem Rev* 1993; **93**: 1753–1769.
- [21] Ridley CP, Faulkner DJ, Haygood MG. Investigation of *Oscillatoria spongeliae* dominated bacterial communities in four dictyoceratid sponges. *Appl Environ Microbiol* 2005; **71**: 7366–7375.
- [22] Sabdono A, Radjasa OK. Microbial symbionts in marine sponges: marine natural product factory. *J Coastal Dev* 2008; **11**(2): 57–61.
- [23] Blunt JW, Copp BR, Munro MHG, Northcote PT, Prinsep MR. Marine natural products. *Nat Prod Rep* 2006; **23**: 26–78.
- [24] Bugni TS, Ireland CM. Marine-derived fungi: a chemically and biologically diverse group of microorganisms. *Nat Prod Rep* 2004; **21**: 143–163.
- [25] Saleem M, Ali MSS, Hussain JA, Ashraf M, Lee YS. Marine natural products of fungal origin. *Nat Prod Rep* 2007; **24**: 1142–1152.
- [26] Faulkner DJ. Marine natural products. *Nat Prod Rep* 2000; **17**: 7–55.
- [27] Sipkema D, Franssen MCR, Osinga R, Tramper J, Wijffels RH. Marine sponges as pharmacy. *Mar Biotechnol* 2005; **7**: 142–146.
- [28] Suda M, Mugishima T, Komatsu K, Sone T, Tanaka M, Mikami Y, et al. Speradine A, a new pentacyclic oxindole alkaloid from a marine-derived fungus *Aspergillus tamari*. *Tetrahedron* 2003; **59**: 3227–3230.
- [29] Kato H, Yoshida T, Tokue T, Nojiri Y, Hirota H, Ohta T, et al. Notoamides A–D: prenylated indole alkaloids isolated from a marine-derived fungus, *Aspergillus* sp. *Angew Chem Int Ed* 2007; **46**: 2254–2256.
- [30] Fremlin LJ, Piggott AM, Lacey E, Capon RJ. Cottoquinazoline A and Cotteslosins A and B, metabolites from an Australian marine-derived strain of *Aspergillus versicolor*. *J Nat Prod* 2009; **72**: 666–670.
- [31] Meenupriya J, Thangaraj M. Isolation and molecular characterization of bioactive secondary metabolites from *Callyspongia* spp. associated fungi. *Asian Pac J Trop Med*. 2010; **10**: 738–740.
- [32] Lazzarini L, Cavaletti G, Toppo, Marinelli F. Rare genera of actinomycetes as potential producers of new antibiotics. *Antonie Leeuwenhoek*. 2000; **78**: 399–405.